Dr. Friedman is author of Building Biotechnology, which has been used by dozens of MBA programs and graduate programs in biotechnology. Dr. Friedman also publishes the Journal of Commercial Biotechnology has been described as "A Harvard Business Review for Biotechnology Companies"
Dr. Friedman developed the DrugPatentWatch.com database in 2002. It provides deep knowledge on global drug patents and generic entry for clients throughout the drug discovery-development-delivery chain.
Dr. Friedman has been ranking global biotechnology for Scientific American since 2009. This ranking has been featured at numerous international conferences, before US federal agencies, and in many national biotechnology development forums.
Bring a global perspective to your event
Dr. Friedman has presented in biotechnology industry development forums for US federal agencies, for international groups, and for individual countries in North America, Europe, and Asia.Set the stage for a productive meeting with an overview of:
Dr. Friedman is publisher of the Journal of Commercial Biotechnology, the authoritative source for leading thinking on biotechnology business management. The Journal of Commercial Biotechnology welcomes research papers, case studies, strategic guidance, and industry perspectives. The JCB also welcomes shorter commentaries on industry developments. More details and sample papers are available at http://www.CommercialBiotechnology.com.
Reach tens of thousands of focused readers with your article in the DrugPatentWatch Resources Section.
With each posting you can expect to reach:
Use the contact form at DrugPatentWatch to suggest a topic. Please include a author headshot/company logo and author/company bio for the byline along with any submissions.
BiotechBlog guest posts are available for informative, non-commercial messages. This non-refereed outlet is more inclusive than the Journal of Commercial Biotechnology and is an excellent outlet for your industry perspectives and practical guidance. Submission guidelines are at http://www.biotechblog.com/spread-your-message-with-biotechblog, and existing guest content is at http://www.biotechblog.com/category/guest-content/.
Please send a short pitch using the BiotechBlog contact form. Please include a author headshot/company logo and author/company bio for the byline along with any submissions.
Yali Friedman, Ph.D., is founder of thinkBiotech and publisher of the Journal of Commercial Biotechnology. His first book, Building Biotechnology, has used as a course text in dozens of biotechnology programs. His other books include Best Practices in Biotechnology Education and Best Practices in Biotechnology Business Development. Scientific American also named Dr. Friedman as one of the 100 most influential people in biotechnology.
Dr. Friedman has strong exposure to leading issues in international biotechnology. He is editor of the Scientific American worldVIEW global biotechnology scorecard, a global biotechnology perspective profiling biotechnology industries and innovation capacity in more than fifty countries, and has been invited to participate in biotechnology industry development forums for US federal agencies, international groups such as APEC and ASEAN, and for individual countries such as Canada, Germany, India, Japan, the Philippines, and Turkey.
Dr. Friedman taught biotechnology management at the National Institutes of Health for several years and continues to regularly guest-lecture for other biotechnology education programs. He writes and speaks on diverse topics such as biotechnology entrepreneurship, strategies to cope with a lack of management talent and capital when developing companies outside of established hubs, and new paradigms in technology-based economic development.
Dr. Friedman has a long history in biotechnology media. He created the first blog on the business of biotechnology for a NY Times web property which was named to Forbes "Best of the Web" list. His other projects include the Student Guide to DNA Based Computers, sponsored by FUJI Television, BiotechBlog.com, and DrugPatentWatch.com, a pharmaceutical industry competitive intelligence platform based on a business plan that was awarded second place in the Panasci Entrepreneurial Awards Competition.